About: Inhaled Hydroxychloroquine to Improve Efficacy and Reduce Harm in the Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhaled Hydroxychloroquine to Improve Efficacy and Reduce Harm in the Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhaled Hydroxychloroquine to Improve Efficacy and Reduce Harm in the Treatment of COVID-19
Creator	Arthur, A Arthur, Aisling Dayton, F Dayton, Francis Farragher, J Farragher, John Healy, A Healy, Anne Kavanagh, O Kavanagh, Oisín Mahoney, B Mahoney, Brian O'reilly, N O'reilly, Niall Pharm, M Res, M Robinson, S Robinson, Shane Walker, G Walker, Gavin
Source	Elsevier; PMC
abstract	Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110110
has license	no-cc
sha1sum (hex)	243d15fcd77669e1a17a5ef21a89bd9bcf661141
schema:url	https://doi.org/10.1016/j.mehy.2020.110110
resource representing a document's title	Inhaled Hydroxychloroquine to Improve Efficacy and Reduce Harm in the Treatment of COVID-19
has PubMed Central identifier	PMC7361049
schema:publication	Med Hypotheses
resource representing a document's body	covid:243d15fcd77669e1a17a5ef21a89bd9bcf661141#body_text
is schema:about of	named entity 'progressed' named entity 'QT interval' named entity 'safety' named entity 'Letter' named entity 'Efficacy' named entity 'Treatment' named entity 'ALMOST ALL' named entity 'RESEARCH' named entity 'HERE' named entity 'managed' named entity 'Study' named entity 'phase II' named entity 'dose' named entity 'registered' named entity 'Reduce' named entity 'Improve' named entity 'prolong the QT interval' named entity 'clinical trials' named entity 'HCQ' named entity 'clinical trials' named entity 'HCQ' named entity 'COVID' named entity 'HCQ' named entity 'Hydroxychloroquine Sulfate' named entity 'side-effects' named entity 'Hydroxychloroquine' named entity 'vaccine' named entity 'azithromycin' named entity 'SARS-CoV-2' named entity 'drug induced' named entity 'antivirals' named entity 'risk factors' named entity 'critically ill' named entity 'COVID' named entity 'COVID' named entity 'side-effects' named entity 'FDA' named entity 'vaccine' named entity 'risk factors' named entity 'SARS-CoV' named entity 'COVID' named entity 'EMA' named entity 'NHS' named entity 'COVID' named entity 'prolong the QT interval' named entity 'HCQ' named entity 'comorbidities' named entity 'hydroxychloroquine' named entity 'ClinicalTrials.gov' named entity 'COVID-19' named entity 'electronic health records' named entity 'treatment options' named entity 'HCQ' named entity 'HCQ' named entity 'clinical trials' named entity 'Chloroquine' named entity 'phase II trials' named entity 'phase II studies' named entity 'Reduce Harm' named entity 'Hydroxychloroquine' named entity 'COVID' named entity 'phase II clinical' covid:arg/243d15fcd77669e1a17a5ef21a89bd9bcf661141 named entity 'Further'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software